Form 4: Zai Lab Executive Rafael Amado Reports Stock Sale

Rafael Amado, a Zai Lab executive, sold 3,000 American Depositary Shares (ADS) on March 17, 2025, at a price of $38.41 per ADS, according to a Form 4 filing.

Summary

• Rafael Amado, President, Head of Global Oncology Research and Development at Zai Lab Ltd, reported a transaction involving the sale of company stock.
• On March 17, 2025, Amado sold 3,000 American Depositary Shares (ADS) at a price of $38.41 per ADS.
• The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 22, 2024.
• Following the transaction, Amado directly owns 30,834 ADSs.
• Each ADS represents ten Ordinary Shares of Zai Lab.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing related to an insider stock sale. The sale was conducted under a pre-arranged trading plan, suggesting it was not based on any sudden negative outlook. Therefore, the sentiment is neutral.

Industry Context

Form 4 filings are a routine part of the US stock market and are required by the SEC to ensure transparency when company insiders trade their company's stock. This allows the public to see if people with inside information are buying or selling stock.

Key Dates

Keywords

Zai Lab, Rafael Amado, ADS, American Depositary Shares, Form 4, Stock Sale, Rule 10b5-1, Insider Trading